Monthly Newsletter April 2016

EFMC-ISMC 2016 - XXIV EFMC International Symposium on Medicinal Chemistry, August 28 - September 1, 2016, Manchester, UK

EFMC-ISMC 2016 will cover drug discovery advances in major therapeutic areas, including the treatment of pain, CNS disorders, anti-infectives, ophthalmology, cardiovascular diseases and oncology. The most recent advances in lead identification and optimization strategies, drug design and profiling technologies will be presented. The impact of biomarkers and imaging at the interfaces between chemistry, biology and experimental medicine will be illustrated. Particular emphasis will be put on first time disclosures, recent highlights in medicinal chemistry and the impact of novel organic synthesis in drug discovery.

Find out more about:


Abstracts for poster presentations can be submitted until June 16. Since the deadline for free abstract submissions has passed since March 23, submissions will be charged 50€ for additional handling costs.



Manchester is a city of radical thinking, inspirational science and world changing first - it is the city where Rutherford first split the atom and Rolls met Royce, it is the home of the first passenger railway station and programmable computer.  Manchester now holds claim to another first, in being awarded the European City of Science 2016. This award comes as recognition of its unique scientific heritage and contribution to scientific discovery, innovation and industry. The city has been at the forefront of scientific innovation since the Industrial Revolution through to the modern age.

The city of Manchester is the third-most visited city in the UK by foreign visitors, after London and Edinburgh. It is notable for its architecture, culture, musical exports, sports clubs and transport connections. Its city centre mixes historic and new architecture rather well, ranging from Victorian to contemporary architecture. The widespread use of red brick characterises the city which has over 135 parks, gardens, and open spaces.

The city is home to a number of museums, among which the Museum of Science & Industry, highlighting Manchester's key role in the Industrial Revolution, and the Manchester Art Gallery, the city's top gallery displaying a superb collection of British art. In Manchester you will of course also find one of the world’s most famous football clubs – Manchester United, as well as top Premier League club Manchester City!

Read more about Manchester on the Visit Manchester website.


EFMC is funding grants for EFMC organised events with the aim to support the participation of young academic scientists. Upon application, up to 50% of the registration fee EFMC-ISMC will be covered by EFMC.

To apply for an EFMC grant, please fill in the application form available on and upload your CV, publication list, abstract, motivation letter and support letter from the supervisor.
Deadline EFMC-ISMC Symposium (August 28 - September 1, 2016): May 17, 2016

Please be informed that following new EFMC regulations, only the members of an EFMC National Adhering Organisation will be allowed to apply for the EFMC grants.

Find out more on:

33rd Camerino-Cyprus Symposium: 'Receptor Chemistry: Reality and Vision'

The 33rd Camerino-Cyprus Symposium will be held in Camerino (Italy) from May 15 until 19, 2016.

The programme of the 33rd Camerino-Cyprus Symposium will include:

  • An opening lecture by Robert J. Lefkowitz (2012 Nobel Prize in Chemisty) - (Duke University Medical Center - USA)
  • 6 sessions
    • "Modeling GPCRs in the Structural Biology Era"
    • "Understanding GPCR-ligand interactions"
    • "Beyond Receptor Chemistry: Transporters"
    • "Advanced Clinical Studies with Drugs for the Treatment of Alzheimer’s and Parkinson’s Disease"
    • "Dopamine D2-like Receptors: From Structure and Function to Potential Therapeutics"
    • "The Future"
  • 28 confirmed lectures

For more information please contact :

Organised by:

EFMC Awards

The EFMC is pleased to announce the recipients of the 2016 Awards:

  • Nauta Award for Pharmacochemistry
  • UCB-Ehrlich Award for Excellence in Medicinal Chemistry
  • Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery

  • Nauta Award for Pharmacochemistry
    Prof. François Diederich – ETH Zürich, Switzerland
  • UCB-Ehrlich Award for Excellence in Medicinal Chemistry
    Dr Paul J. Hergentrother – University of Illinois at Urbana-Champaign, United States
  • Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery
    Prof. Jan Steyaert – VU Brussels, Belgium

The Awards will be presented during the XXIV International Symposium on Medicinal Chemistry (EFMC-ISMC 2016), scheduled to be held on August 28 – September 1, 2016 in Manchester, United Kingdom.

Find out more on

EFMC Prizes

The EFMC is proud to announce the names of the winner and the most meritorious runners-up of the EFMC Prize for a Young Medicinal Chemist in Academia and in Industry.

EFMC Prize for a Young Medicinal Chemist in Industry
Jean Quancard (Novartis Pharma, Switzerland)
Nicolas Desroy (Galapagos, France)
Anne Valade (UCB, Begium)

EFMC Prize for a Young Medicinal Chemist in Academia
Frank Boeckler (Eberhard Karls University Tuebingen, Germany)
Nathaniel Martin (Utrecht University, The Netherlands)
Sylvia Ortega Gutierrez (Universidad Complutense de Madrid, Spain) 

Both Winners will give an oral communication at the XXIV EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2016), in Manchester, UK, on August 28-September 1, 2016.

Report on the 'STOA Working Breakfast on Solving Antibiotic Resistance'

EFMC, EuCheMS and the European Parliament´s STOA (Science and Technology Options Assessment) co-organised the STOA Working Breakfast on Solving Antibiotic Resistance, which took place in Brussels on April 28, 2016.

During this STOA Working Breakfast, researchers and policy-makers analysed the global challenge of AMR and explored possible solutions.

Paul Rübig (STOA Chair) welcomed about 50 participants attending the event, making it a great success amongst the series of STOA Working Breakfasts.

David Cole-Hamilton (President of EuCheMS) gave an introduction on the topic of “Solving Antibiotic Resistance”.

Chris Schofield (University of Oxford, United Kingdom) gave the key message that the need for new antibiotics is growing, but stressed the fact that investments in this field is balanced against current major unmet pharmaceutical needs (e.g. ageing related/neurological diseases) as the private sector will only invest in antibacterial research/development if there is sufficient commercial incentivisation.

Public-private partnerships have the potential to generate new (antibacterial) medicines, but will only do so if funded appropriately.

Chemical synthesis remains a major hurdle in (antibacterial) drug discovery. The EU should consider a large scale international collaborations involving both public and private input with resources sufficient to address potential emergencies as they arise (e.g. acute antibacterial resistance, Ebola, etc).

Lloyd Czaplewski (Chemical Biology Ventures Ltd, United Kingdom) explained the fact that conventional antibiotics may have only been temporary and that we now anticipate a long-term and perhaps never-ending challenge to find new therapies as fast as bacteria become resistant to them, rendering a broader approach to address bacterial infection needed.

A review of alternatives to antibiotics commissioned by the Wellcome Trust and jointly funded by the Department of Health (England) has identified 19 alternative approaches that are being actively explored, but those A2A approaches need adequate funding before delivering new therapies.

Standard antibiotics are of course still needed as most advanced A2A projects target single species of bacteria, rather than the 20 to 30 species targeted by broad-spectrum antibiotics. 

Philippe Glaser (Institut Pasteur, France) delivered the message that bacterial pathogens develop resistance to almost all the antibiotics available nowadays, while no new classes of antibiotics have come to the market for more than 25 years, and drugs we do have are over-prescribed.

Antibiotics resistance is a strategic issue of major global public health importance, a massive threat where the previous strategies (i.e. developing powerful antimicrobials) have failed because selection for resistance inevitably occurs.

A large effort is necessary not only to generate new antimicrobial drugs but also to understand the many factors that lead to the emergence of resistance, for bacterial, fungal and parasitic resistance.

Professor Koen Augustyns (EFMC President) attended the meeting on behalf of EFMC.

The EFMC wanted to thank all participants for their attendance, all contributors to this project and would like to congratulate the EFMC Working group on “Influence on European science policy”, chaired by Anders Karlén, for this first success towards their goal.  

'New Talent: Europe themed issue' by MedChemComm has been published

This themed issue, guest edited by Professors Gerhard Ecker, Koen Augustyns and Uli Stilz, showcases some of the top research from emerging investigators from Europe. This issue covers medicinal chemistry research in its broadest sense, and showcases the strength of research being carried out by tomorrow's leaders in the field.

Link to the themed issue

News from the Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry (RSC)

The Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry (RSC) is pleased to announce:

  • Kinase 2016: 7th RSC / SCI symposium on Kinase Inhibitor Design on 16th May 2016, Nottingham, UK
  • 6th RSC / SCI symposium on GPCRs in Medicinal Chemistry on 13th to 15th June 2016, Aptuit, Verona, Italy

Kinase 2016:  7th RSC / SCI symposium on Kinase Inhibitor Design on 16th May 2016, Nottingham, UK

Synopsis:  Perturbation of cell signalling through inhibition of kinase enzymes has delivered nearly 30 approved medicines to date. The meeting will feature several highly pertinent themes including new approaches and technologies to modulate and measure kinase function as well as diverse medicinal chemistry case studies. The symposium will also draw on the lessons from history to provide insight into the future direction of the field


6th RSC / SCI symposium on GPCRs in Medicinal Chemistryon 13th to 15th June 2016, Aptuit, Verona, Italy

Please note that the closing date for submission of poster abstracts is 19th April 2016

Synopsis:  The key role of G-protein coupled receptors (GPCRs) in human disease underpins their importance to modern medicine. We are pleased to announce that Aptuit, Italy will support the sixth meeting in this series on GPCR drug discovery, which will combine cutting edge medicinal chemistry with innovative structural biology and novel drug design approaches.




Founded in 2001, GalChimia has become the Spanish leader in synthetic organic chemistry. Our expert, dedicated team of chemists has found a productive outlet for their obsession with chemistry, providing services to clients worldwide.

More info


September 6-7, 2018
Ljubljana, Slovenia
5th EFMC Young Medicinal Chemist Symposium (EFMC-YMCS 2018)


June 22, 2018
Madrid, Spain
V SEQT Young Researchers Symposium

June 27, 2018
Dublin, Ireland
2nd Medicinal Chemistry Ireland Conference

November 12-13, 2018
London, United Kingdom
2nd SCI/RSC Symposium on Antimicrobial Drug Discovery



September 19-21, 2018
Rimini, Italy
Summer School in Pharmaceutical Analysis (SSPA)

October 7-12, 2018
Leysin, Switzerland
13th Swiss Course on Medicinal Chemistry


Medicinal / Synthetic Organic Chemists, Concept Life Sciences: Drug Discovery, Sandwich, Kent, United Kingdom

Read more

MsC student or PhD internship, KU Leuven: Cellular and Molecular Medicine, Leuven, Belgium

Read more

Find us on social media

EFMC Facebook EFMC Twitter EFMC LinkedIn EFMC Instagram